Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 256.08B +6.6% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | 795.62M |
| PE Ratio | 19.99 |
| Forward PE | 15.94 |
| Dividend | 9.80 (3.06%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 437,603 |
| Average Volume | 1,202,069 |
| Open | 322.00 |
| Previous Close | 320.70 |
| Day's Range | 317.40 - 323.50 |
| 52-Week Range | 231.90 - 374.90 |
| Beta | 0.21 |
| RSI | 29.47 |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsNews
Roche Secures CE Mark For First Blood Test To Identify ApoE4 Carriers In Alzheimer's Disease
(RTTNews) - Roche (RHHBY) has received CE Mark approval for the Elecsys ApoE4 test, the first in-vitro diagnostic immunoassay that can identify carriers of the ApoE4 genetic variant using a simple blo...
Roche (RHHBY) Gains CE Mark for Alzheimer's Biomarker Test
Roche (RHHBY) Gains CE Mark for Alzheimer's Biomarker Test
Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4 genetic variant using a simple blood sample. The test offers a fast, reliable a...
What's Going On With Olema Pharmaceuticals Stock On Wednesday?
Olema Pharmaceuticals' stock drops after Roche breast cancer study misses key goal. Investors weigh trial results and outlook for Palazestrant. ... Full story available on Benzinga.com
Roche Shareholders Approve All Proposals At 2026 Annual Meeting
(RTTNews) - Roche Holding AG (RHHBY), a pharmaceutical company, announced on Tuesday, that its shareholders approved all proposals presented by the Board of Directors at the company's 2026 Annual Gene...
Roche Annual General Meeting 2026
Basel, 10 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting. The 594 shareholders in ...
Glooko to Expand EMEA CGM Connectivity with Roche Accu-Chek® SmartGuide Integration
GOTHENBURG, Sweden--(BUSINESS WIRE)--Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing challenges of glycemic safety and diabetes m...
Strait of Hormuz will partially reopen in 2-3 weeks: David Roche
Quantum Strategy' David Roche says he expects oil reserves can sufficiently support world demand, and that the 'world won't run out of oil'. He also explains why he believes Iran can't afford to escal...
Why Is Olema Pharmaceuticals Stock Dropping On Monday?
In November 2025, Olema Pharmaceuticals surged over 200% after Roche released phase 3 results from a lidERA Breast Cancer study. ... Full story available on Benzinga.com
Roche Tumbles, Taking Olema With It, On A High-Profile Failure
Roche stock tumbled Monday — giving way to steeper losses for Olema — after its oral breast cancer treatment failed in final-phase testing.
Roche's Breast Cancer Drug Falls Short In Phase 3 Study
Roche Holdings AG (OTC: RHHBY) on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients . Trial Misses Primary Goa...
Roche (RHHBY) Shares Drop After Breast Cancer Drug Trial Misses Goal
Roche (RHHBY) Shares Drop After Breast Cancer Drug Trial Misses Goal
Roche Shares Drop Up to 7.5% After Breast Cancer Pill Misses Trial Goal
Roche Shares Drop Up to 7.5% After Breast Cancer Pill Misses Trial Goal
Roche shares drop as oral breast cancer drug fails in trial
Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate giredestrant against a common form of breast cancer can help newly diagnosed pa...
Genentech: PersevERA Breast Cancer Study Fails To Meet Primary Objective
(RTTNews) - Genentech, a member of the Roche Group (RO.SW, ROG.SW), announced results from the Phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbo...
Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study
The combination of Roche's investigational drug, giredestrant, with Pfizer's Ibrance didn't lead to a statistically significant improvement among patients with advanced breast cancer.
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating i...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
Basel, 9 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbocicli...
2 Underrated Weight Loss Stocks to Buy Now
Regeneron has a pair of weight-loss candidates close to entering late-stage studies. Roche's recent mid-stage readout positions it as a strong contender in the weight loss market.
Roche (RHHBY) Diagnostics Division Faces Tariff Challenges
Roche (RHHBY) Diagnostics Division Faces Tariff Challenges
Roche chairman still expects diagnostics hit from US tariffs
Roche expects its agreement with the U.S. government will keep its medicines exempt from the current round of import tariffs, but its diagnostics division remains exposed and could face renewed duti...
Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics'
Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7% weight-loss over 42 weeks.
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Basel, 06 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the phase III ALLEGORY trial of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus ery...
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (...
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms Gazyva/Gazyvaro has th...